Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nitin Gupta

Showing results (571-580 of 590) with videos related to

Pageof 59
Sort By:
Biorxiv : the Preprint Server for Biology|July 16, 2025
Sensitizing Immune-Refractory Ovarian Tumors via p53 Mutation-Tailored ImmunotherapyRishita Chatterjee, Arturo Simoni-Nieves, An Truong, et al.
Expert Review of Anti-Infective Therapy|November 14, 2020
Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic reviewBetsy Ann Joseph, Mahmoud Dibas, Kirk W Evanson, et al.
Medicine|May 20, 2021
Corticosteroid therapy for COVID-19: A systematic review and meta-analysis of randomized controlled trialsYashwitha Sai Pulakurthi, John M Pederson, Kavitha Saravu, et al.
Journal of Clinical Apheresis|February 5, 2021
Efficacy of convalescent plasma therapy for COVID-19: A systematic review and meta-analysisCharan T R Vegivinti, John M Pederson, Kavitha Saravu, et al.
Nature|June 1, 2018
Author Correction: High-fat diet enhances stemness and tumorigenicity of intestinal progenitorsSemir Beyaz, Miyeko D Mana, Jatin Roper, et al.
Nature|March 4, 2016
High-fat diet enhances stemness and tumorigenicity of intestinal progenitorsSemir Beyaz, Miyeko D Mana, Jatin Roper, et al.
Inflammatory Bowel Diseases|May 23, 2018
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel DiseaseEugenia Shmidt, Gursimran Kochhar, Justin Hartke, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 10, 2019
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative ColitisDavid M Faleck, Adam Winters, Shreya Chablaney, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 1, 2018
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel DiseasesJoseph Meserve, Satimai Aniwan, Jenna L Koliani-Pace, et al.
Inflammatory Bowel Diseases|May 4, 2019
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease OutcomesJenna L Koliani-Pace, Siddharth Singh, Michelle Luo, et al.
Pageof 59

Showing results (571-580 of 590) with videos related to

Sort By:
Pageof 59
Biorxiv : the Preprint Server for Biology|July 16, 2025
Sensitizing Immune-Refractory Ovarian Tumors via p53 Mutation-Tailored ImmunotherapyRishita Chatterjee, Arturo Simoni-Nieves, An Truong, et al.
Expert Review of Anti-Infective Therapy|November 14, 2020
Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic reviewBetsy Ann Joseph, Mahmoud Dibas, Kirk W Evanson, et al.
Medicine|May 20, 2021
Corticosteroid therapy for COVID-19: A systematic review and meta-analysis of randomized controlled trialsYashwitha Sai Pulakurthi, John M Pederson, Kavitha Saravu, et al.
Journal of Clinical Apheresis|February 5, 2021
Efficacy of convalescent plasma therapy for COVID-19: A systematic review and meta-analysisCharan T R Vegivinti, John M Pederson, Kavitha Saravu, et al.
Nature|June 1, 2018
Author Correction: High-fat diet enhances stemness and tumorigenicity of intestinal progenitorsSemir Beyaz, Miyeko D Mana, Jatin Roper, et al.
Nature|March 4, 2016
High-fat diet enhances stemness and tumorigenicity of intestinal progenitorsSemir Beyaz, Miyeko D Mana, Jatin Roper, et al.
Inflammatory Bowel Diseases|May 23, 2018
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel DiseaseEugenia Shmidt, Gursimran Kochhar, Justin Hartke, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 10, 2019
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative ColitisDavid M Faleck, Adam Winters, Shreya Chablaney, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 1, 2018
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel DiseasesJoseph Meserve, Satimai Aniwan, Jenna L Koliani-Pace, et al.
Inflammatory Bowel Diseases|May 4, 2019
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease OutcomesJenna L Koliani-Pace, Siddharth Singh, Michelle Luo, et al.
Pageof 59